DXP Enterprises (NASDAQ:DXPE) vs. Capstone Therapeutics (NASDAQ:CAPS) Head-To-Head Analysis

Capstone Therapeutics (NASDAQ:CAPS) and DXP Enterprises (NASDAQ:DXPE) are both industrials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Capstone Therapeutics and DXP Enterprises”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11 million	0.07	-$21.23 million	($3.35)	-0.06
DXP Enterprises	$2.14 billion	1.43	$88.68 million	$5.68	34.79

DXP Enterprises has higher revenue and earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than DXP Enterprises, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Capstone Therapeutics and DXP Enterprises, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1	0	0	0	1.00
DXP Enterprises	0	2	3	0	2.60

DXP Enterprises has a consensus price target of $187.00, indicating a potential downside of 5.37%. Given DXP Enterprises’ stronger consensus rating and higher possible upside, analysts clearly believe DXP Enterprises is more favorable than Capstone Therapeutics.

Insider and Institutional Ownership

2.5% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of DXP Enterprises shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by company insiders. Comparatively, 22.0% of DXP Enterprises shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Capstone Therapeutics has a beta of -1.52, suggesting that its stock price is 252% less volatile than the S&P 500. Comparatively, DXP Enterprises has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Capstone Therapeutics and DXP Enterprises’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-36.51%	-144.43%	-40.48%
DXP Enterprises	4.35%	18.51%	5.70%

Summary

DXP Enterprises beats Capstone Therapeutics on 13 of the 14 factors compared between the two stocks.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

About DXP Enterprises

DXP Enterprises, Inc., together with its subsidiaries, engages in distributing maintenance, repair, and operating (MRO) products, equipment, and services in the United States and Canada. It operates through three segments: Service Centers (SC), Supply Chain Services (SCS), and Innovative Pumping Solutions (IPS). The SC segment offers MRO products, equipment, and integrated services, including technical expertise and logistics services. It offers a range of MRO products in the rotating equipment, bearing, power transmission, hose, fluid power, metal working, fastener, industrial supply, safety products, and safety services categories. This segment serves customers in the oil and gas, food and beverage, petrochemical, transportation, other general industrial, mining, construction, chemical, municipal, agriculture, and pulp and paper industries. The SCS segment manages procurement and inventory vinventory optimization and management, storeroom management, transaction consolidation and control, vendor oversight and procurement cost optimization, productivity improvement, and customized reporting services. Its programs include SmartAgreement, a procurement solution for various MRO categories; SmartBuy, an on-site or centralized MRO procurement solution; SmartSource, an on-site procurement and storeroom management solution; SmartStore, an e-Catalog solution; SmartVend, an industrial dispensing solution; and SmartServ, an integrated service pump solution. The IPS segment fabricates and assembles custom-made pump packages; remanufactures pumps; and manufactures branded private label pumps. DXP Enterprises, Inc. was founded in 1908 and is based in Houston, Texas.